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Lobomycosis in 
Inshore and 
Estuarine Dolphins
To the Editor: Lobomycosis is a 
chronic dermal infectious disease af-
fecting humans and some species of 
dolphins but not, to date, freshwater 
dolphins. Because this disease is still 
considered rare despite the increasing 
number of reported cases in humans 
and cetaceans, clinical and epidemio-
logic information must be accurately 
reported to help clarify many of the 
unknown aspects of this disease.
We address this point because 
after carefully reading the excellent 
report by Elsayed et al. on the ﬁ  rst hu-
man case of lobomycosis in Canada, 
we noticed that the authors describe 
the natural disease as occurring in hu-
mans and marine and freshwater dol-
phins only (1). However, this informa-
tion is only partially correct because 
to date lobomycosis has not been de-
scribed in freshwater dolphins. What 
is more worrisome is that this infor-
mation is beginning to be referenced 
in other published articles (2). So far, 
lobomycosis has been conﬁ  rmed in 2 
species of inshore and estuarine Del-
phinidae: 1) the common bottlenose 
dolphin (Tursiops truncatus) from 
Brazil, the Atlantic coast of the United 
States, and Europe and 2) the Guiana 
dolphin (Sotalia guianensis) from the 
Surinam River estuary (3–8).
The fact that lobomycosis is en-
demic in humans in the Amazon basin 
could logically raise the suspicion that 
other animal species in this area may 
act as reservoirs or even be affected by 
the disease. However, the infection has 
never, to our knowledge, been reported 
in botos (Inia geoffrensis) or tucuxis 
(Sotalia ﬂ  uviatilis) from the Amazon 
and Orinoco Rivers. Preliminary ﬁ  eld 
studies, like the one carried out by da 
Silva et al., failed to demonstrate the 
disease in any of the 385 live-captured 
I. geoffrensis boto specimens from the 
Mamirauá Reserve in the central Am-
azon region of Brazil (9); similarly, 
our observational studies in the Ven-
ezuelan Orinoco River failed to detect 
the disease. On the other hand, despite 
the absence of indigenous cases of 
lobomycosis in humans reported in the 
United States, the disease is endemic 
in dolphins from the Indian River La-
goon in Florida (7), suggesting that 
no apparent epidemiologic link may 
exist between humans and cetaceans. 
Unfortunately, the etiologic agent of 
lobomycosis, Lacazia loboi (Figure), 
has not been cultured in vitro (10) de-
spite exhaustive attempts, making its 
isolation from probable and suspected 
environmental sources impossible.
Dolphin-to-human transmission 
of lobomycosis has been reported only 
1 time; the case-patient was an aquari-
um attendant who had had close phys-
ical contact with an affected dolphin 
(5). However, because the possibility 
of zoonotic transmission of this dis-
ease remains latent and because many 
pathologic and clinical aspects of the 
disease remain poorly understood, it is 
imperative to clarify these ecological 
concepts. Up-to-date molecular epide-
miology studies to compare the strains 
affecting humans and dolphins and 
their possible phylogenetic relation-
ship are needed.
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Variations in 
Leprosy 
Manifestations 
among HIV-Positive 
Patients, Manaus, 
Brazil 
To the Editor: Contrary to early 
expectations, the co-occurrence of lep-
rosy and HIV has not increased glob-
ally (1). However, most of the larger 
studies on the subject were conducted 
in the early to mid-1990s in African 
countries, and the research designs 
had limited power to describe the true 
effects of co-infection (1). Moreover, 
the introduction of highly active an-
tiretroviral therapy (HAART), which 
has been used routinely in Brazil since 
1996, altered the clinical evolution of 
HIV infection (2) and led to increas-
ing reports of immune restoration 
inﬂ   ammatory syndrome (IRIS) as-
sociated with leprosy (3,4). Although 
some researchers have argued that 
this association may not affect public 
health (2), its true importance remains 
to be clariﬁ  ed. Finally, leprosy has a 
wide range of clinical manifestations, 
which sometimes imposes a clinical 
challenge and may lead to misdiag-
nosis (5). Together, these factors may 
have helped mask the true scenario of 
leprosy and HIV co-infection, particu-
larly in areas where these conditions 
are highly endemic. In this context, 
case reports from referral centers 
that reﬂ  ect the broad clinical aspects 
of leprosy and HIV co-occurrence 
are important to increase clinicians’ 
awareness of both diseases.
We report 3 HIV-positive/AIDS 
patients who showed different clinical 
manifestations of leprosy; their condi-
tions were diagnosed before and after 
HAART initiation. All patients lived 
in Manaus, the capital of the state of 
Amazonas in Brazil, an area where 
both leprosy and HIV infection are 
endemic. The 3 patients represent a 
sample from our 11-year experience 
with 21 patients with leprosy and HIV 
co-infection. 
Patient 1 was a 29-year-old 
woman whose HIV-1 infection was 
diagnosed in May 2002 at antenatal 
examination. Her CD4 cell count in 
2002 was 513 cells/μL. In Novem-
ber 2007, she sought treatment at 
the Institute of Tropical Medicine of 
Amazonas with a 3-month history of a 
single erythematous plaque on her left 
arm, which was clinically diagnosed 
as borderline tuberculoid (BT) lep-
rosy. The patient’s sensitivity to pain 
was decreased. There was no nerve 
enlargement. Histopathologic exami-
nation conﬁ  rmed the diagnosis, show-
ing a granulomatous dermatitis with 
no acid-fast bacilli on Wade stain. At 
this time, her CD4 cell count was 342 
cells/μL. HAART and multidrug ther-
apy (MDT) for paucibacillary leprosy 
were initiated. The leprosy resolved, 
and the lesion disappeared within 2 
months of therapy.
Patient 2 was a 22-year-old man 
who had neurocryptococcosis and 
HIV infection diagnosed in September 
2007. At that time, he exhibited dis-
seminated, inﬁ   ltrated lesions on the 
trunk and upper and lower limbs. Bor-
derline lepromatous (BL) leprosy was 
clinically diagnosed. Skin biopsy con-
ﬁ  rmed the diagnosis; the biopsy speci-
men showed a granulomatous dermati-
tis, foamy cells, and multiple acid-fast 
bacilli. His CD4 cell count was 6 cells/
μL. HAART and MDT for multibacil-
lary leprosy were prescribed. In Feb-
ruary 2008, the patient was readmitted 
to the Institute of Tropical Medicine 
of Amazonas and died of nonspeciﬁ  ed 
bacterial pneumonia and sepsis.
Patient 3 was a 23-year-old wom-
an who had HIV-1 infection (CD4 cell 
count 435 cells/μL) diagnosed in No-
vember 2006 at antenatal examination. 
HAART was begun 3 months later. In 
August 2008, she sought treatment 
with a 3-month history of a single 
patch on the left leg with erythematous 
papules on its border (Figure). There 
was decreased pain sensitivity in the 
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